WVE — Wave Life Sciences Balance Sheet
0.000.00%
- $1.03bn
- $738.76m
- $108.30m
- 18
- 11
- 70
- 24
Annual balance sheet for Wave Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 184 | 151 | 88.5 | 200 | 302 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 30 | 0 | — | 21.1 | 1.42 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 230 | 163 | 98.5 | 235 | 320 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 45.4 | 40.6 | 44.1 | 35.7 | 28 |
Other Long Term Assets | |||||
Total Assets | 279 | 207 | 146 | 275 | 352 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 121 | 64.2 | 71.5 | 186 | 111 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 189 | 167 | 184 | 227 | 135 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 90.7 | 40.4 | -37.2 | 47.5 | 217 |
Total Liabilities & Shareholders' Equity | 279 | 207 | 146 | 275 | 352 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |